Biomarkers /
IGL
Overview
Immunoglobulin lambda locus (IGL) is a gene that encodes for a variable region in immunoglobulins, protein complexes that recognize foreign antigens and initiate immune responses. Amplification is observed in prostate cancer.
IGL is altered in 0.19% of all cancers with breast invasive ductal carcinoma, diffuse large B-cell lymphoma, not otherwise specified, endometrial endometrioid adenocarcinoma, bladder urothelial carcinoma, and Burkitt lymphoma having the greatest prevalence of alterations [3].
The most common alterations in IGL are IGL-MYC Fusion (0.18%), IGL-BCL2 Fusion (0.04%), IGL Fusion (0.03%), and IGL-TTC28 Fusion (1.09%) [3].
Clinical Trials
Significance of IGL in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.